Get the Stockscreener App
0.218
5.31%
0.011
Processa Pharmaceuticals Inc stock is traded at $0.218, with a volume of 6.35M.
It is up +5.31% in the last 24 hours and down -12.70% over the past month.
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).
See More
Previous Close:
$0.207
Open:
$0.207
24h Volume:
6.35M
Relative Volume:
0.36
Market Cap:
$10.98M
Revenue:
-
Net Income/Loss:
$-11.53M
P/E Ratio:
-0.0452
EPS:
-4.82
Net Cash Flow:
$-11.12M
1W Performance:
+0.88%
1M Performance:
-12.70%
6M Performance:
-58.87%
1Y Performance:
-85.27%
1-Day Range:
$0.202
$0.225
1-Week Range:
$0.1939
$0.225
52-Week Range:
$0.15
$1.5199
Processa Pharmaceuticals Inc Stock (PCSA) Company Profile
Name
Processa Pharmaceuticals Inc
Sector
Industry
Phone
443-776-3133
Address
601 21ST STREET, SUITE 300, VERO BEACH
Compare PCSA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PCSA
Processa Pharmaceuticals Inc
|
0.218 | 12.12M | 0 | -11.53M | -11.12M | -4.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Processa Pharmaceuticals Inc Stock (PCSA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-25-24 | Initiated | H.C. Wainwright | Buy |
Processa Pharmaceuticals Inc Stock (PCSA) Latest News
Is Processa Pharmaceuticals Inc. a candidate for recovery play2025 Technical Overview & Risk Controlled Swing Trade Alerts - Newser
Will Processa Pharmaceuticals Inc. price bounce be sustainableGap Down & Risk Adjusted Buy and Sell Alerts - Newser
Full technical analysis of Processa Pharmaceuticals Inc. stockTrade Analysis Report & Daily Oversold Bounce Ideas - Newser
Using data tools to time your Processa Pharmaceuticals Inc. exitMarket Sentiment Review & Risk Adjusted Buy/Sell Alerts - Newser
How hedge fund analytics apply to Processa Pharmaceuticals Inc. stockForecast Cut & AI Based Buy and Sell Signals - Newser
Chart based analysis of Processa Pharmaceuticals Inc. trends2025 Bull vs Bear & Daily Market Momentum Tracking - Newser
News impact scoring models applied to Processa Pharmaceuticals Inc.Quarterly Trade Review & High Accuracy Trade Alerts - Newser
How to use a screener to detect Processa Pharmaceuticals Inc. breakoutsForecast Cut & Weekly Setup with ROI Potential - Newser
Is it time to cut losses on Processa Pharmaceuticals Inc.July 2025 Recap & Reliable Entry Point Trade Alerts - Newser
Published on: 2025-08-18 00:26:16 - Newser
Real time breakdown of Processa Pharmaceuticals Inc. stock performanceMarket Activity Report & Weekly Breakout Stock Alerts - Newser
Can momentum traders help lift Processa Pharmaceuticals Inc.Weekly Trade Review & Daily Chart Pattern Signal Reports - Newser
Processa Pharmaceuticals Inc. Earnings Report Breakdown: What Investors Should Know2025 Stock Rankings & Growth Oriented Trading Recommendations - Newser
What technical models suggest about Processa Pharmaceuticals Inc.’s comebackOptions Play & Risk Controlled Stock Pick Alerts - Newser
Volatility clustering patterns for Processa Pharmaceuticals Inc.2025 Market WrapUp & Free Technical Confirmation Trade Alerts - Newser
Key External Factors That Drive Processa Pharmaceuticals Inc. Stock Price Movements2025 Momentum Check & Weekly Sector Rotation Insights - Newser
Processa Pharmaceuticals Inc. stock trend forecastM&A Rumor & Safe Entry Point Identification - Newser
What makes Processa Pharmaceuticals Inc. stock price move sharplyOptions Play & Free Growth Oriented Trading Recommendations - Newser
Institutional scanner results for Processa Pharmaceuticals Inc.Earnings Trend Report & Weekly High Return Forecasts - Newser
Processa Pharmaceuticals secures strategic investment, evaluates corporate crypto treasury strategies. - AInvest
What indicators show strength in Processa Pharmaceuticals Inc.Quarterly Market Review & Long Hold Capital Preservation Plans - Newser
Does Processa Pharmaceuticals Inc. qualify in momentum factor screeningTrade Analysis Report & Fast Momentum Entry Tips - Newser
Can technical indicators confirm Processa Pharmaceuticals Inc.’s reversalReal Time Screener for Growth Trades - Newser
How Processa Pharmaceuticals Inc. stock performs during market volatilityChart Driven Entry Timing for Swing Trades - Newser
Is This the Dip to Buy in Processa Pharmaceuticals Inc.Consistent Income Focused Trade List Analyzed - beatles.ru
Processa Pharmaceuticals Inc. Ranks High in Smart Money TrackerTechnical Breakout Signal Plan Review - beatles.ru
Is Processa Pharmaceuticals Inc. Stock a Smart Buy in 2025 Investment Analysis InsideFree High Yield Stocks With Buy Confirmation - Newser
Top Risks to Consider Before Buying Processa Pharmaceuticals Inc. StockFree Top Gaining Picks With Entry Signals - Newser
How to use Fibonacci retracement on Processa Pharmaceuticals Inc.Free Chart Breakout Buy Signal Detection - Newser
Why Processa Pharmaceuticals Inc. is moving todayPrice Movement and Market Sentiment Analysis - Newser
Processa Pharmaceuticals Inc expected to post a loss of 12 cents a shareEarnings Preview - TradingView
Processa Pharmaceuticals Reports Increased Losses Amid Strategic Developments - TipRanks
Biotech-Fintech Synergy in Capital Strategy: How Processa Pharmaceuticals' Crypto Treasury Initiative Could Reshape Shareholder Value - AInvest
Processa Pharmaceuticals, Inc. SEC 10-Q Report - TradingView
Processa Pharmaceuticals explores cryptocurrency treasury strategy By Investing.com - Investing.com Nigeria
Processa Pharmaceuticals explores cryptocurrency treasury strategy - Investing.com
Processa Pharmaceuticals Secures Strategic Investment and Evaluates Corporate Crypto Treasury Strategies - Koreabizwire
Processa Pharmaceuticals Inc Stock (PCSA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Processa Pharmaceuticals Inc Stock (PCSA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Ng George K | Chief Executive Officer |
Jan 27 '25 |
Buy |
0.80 |
87,200 |
69,542 |
87,200 |
| Young David | Pres. Research & Development |
Jan 27 '25 |
Buy |
0.80 |
124,500 |
99,289 |
205,405 |
| Lin Patrick | Chief Business - Strategy Off |
Jan 27 '25 |
Buy |
0.80 |
43,500 |
34,691 |
43,500 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):